A Case of Successful Use of a Combination of Local Necrotizing Therapy and Immunostimulation in the Treatment of a Patient with Late‑Stage Lung Cancer
https://doi.org/10.37174/2587-7593-2024-7-1-82-91
Abstract
Lung cancer remains a global cancer problem. Recent studies have focused on the effectiveness of new combinations of immunological and targeted drugs. A clinical observation of the successful use of a combination of locally destructive effects — endobronchial photodynamic therapy and radiation therapy with immunostimulation with domestic recombinant interleukin — 2 in the treatment of a patient with late‑stage lung cancer is presented. To date, 41 months (3.5 years) have passed since the patient’s treatment and diagnosis. The patient’s condition is satisfactory, he does not complain, physical activity is completely preserved.
About the Authors
V. G. IvshinRussian Federation
Vladislav G. Ivshin— Professor of the Department of Surgical Diseases of the Medical Institute of the Tula State University, General Director of the Center for New Medical Technologies, Tula, Doctor of Medical Sciences, Associate Professor
300123, Tula, Boldina str., 128,
300031, Tula, Metallurgov str., 83a
AuthorID: 698757
G. V. Kornienko
Russian Federation
Grigory V. Kornienko — Candidate of Medical Sciences, Assistant of the Department of Surgical Diseases of the Medical Institute of the Tula State University, Anesthesiologist‑Resuscitator, Center for New Medical Technologies LLC
300123, Tula, Boldina str., 128,
300031, Tula, Metallurgov str., 83a
A. S. Petnyunas
Russian Federation
Aleksey S. Petnyunas — Surgeon of the Department of Thoracic Surgery
300053, Tula, 1a Yablochkova str.
References
1. Lung cancer remains a global problem in oncology. www.niionkologii.ru/institute/pressa/index?id=2366 (In Russ.).
2. Brahmer JR, Rodríguez Abreu D, Robinson AG, et al. Health related quality of life results for pembrolizumab versus chemotherapy in advanced, PD L1 positive NSCLC (KEYNOTE 024): a multicentre, international, randomized, open label phase 3 trial. Lancet Oncol. 2017 Dec; 18(12): 1600-9.
3. Tyulyandin SA. Immunotherapy as the first line of systemic therapy of metastatic non small cell lung cancer. https://rosoncoweb.ru/news/oncology/2018/09/24 1/ (In Russ.).
4. Tyulyandin S.A. ASCO20: Achievements in the treatment of metastatic lung cancer. https://rosoncoweb.ru/news/oncology/2020/06/15 4/ (In Russ.).
Review
For citations:
Ivshin V.G., Kornienko G.V., Petnyunas A.S. A Case of Successful Use of a Combination of Local Necrotizing Therapy and Immunostimulation in the Treatment of a Patient with Late‑Stage Lung Cancer. Journal of oncology: diagnostic radiology and radiotherapy. 2024;7(1):82-91. (In Russ.) https://doi.org/10.37174/2587-7593-2024-7-1-82-91